日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

INBRX-120 是一种靶向 CD8α 的失谐 IL-2,可选择性扩增和激活杀肿瘤效应细胞,从而实现安全持久的体内反应

Florian J Sulzmaier, Nadja Kern, Sae Jeong Ahn, Anya Polovina, Jason Ho, Abrahim Hussain, Garrett Cyprus, Chelsie Macedo, Rajay Pandit, William Crago, Emily Rowell, John C Timmer, Brendan P Eckelman

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

INBRX-109(一种第三代重组人源化死亡受体5激动剂抗体)在软骨肉瘤中的临床前表征和I期试验结果

Vivek Subbiah ,Sant P Chawla ,Anthony P Conley ,Breelyn A Wilky ,Anthony Tolcher ,Nehal J Lakhani ,David Berz ,Vasily Andrianov ,William Crago ,Monica Holcomb ,Abrahim Hussain ,Carson Veldstra ,James Kalabus ,Brianne O'Neill ,Lane Senne ,Emily Rowell ,Analeah B Heidt ,Katelyn M Willis ,Brendan P Eckelman